Piper Sandler has initiated coverage on Abbott Laboratories (ABT), highlighting the company’s diversified business model, strong growth potential, and attractive valuation despite ongoing litigation. Analyst Adam C. Maeder initiated coverage with an Overweight rating and a price target of $131, citing Abbott’s solid growth prospects and discount compared to its peers.
Abbott Laboratories is recalling certain FreeStyle Libre 3 sensors due to potential inaccurate high glucose readings. The faulty sensors could lead to serious health risks, including severe hypoglycemia. Abbott has also launched Lingo, a prescription-free continuous glucose monitoring system, for individuals seeking to improve their overall health.
This article examines the role of analyst recommendations in investment decisions, using Abbott Laboratories (ABT) as an example. It explores the reliability of brokerage recommendations and compares them to the Zacks Rank, a quantitative stock rating tool. The article concludes that while analyst recommendations can offer some insights, they should be used with caution and validated by other analytical tools like the Zacks Rank, which is driven by earnings estimate revisions.
CNBC’s ‘Halftime Report Final Trades’ featured discussions on Abbott Laboratories, iShares U.S. Industrials ETF, and Nu Holdings. Karen Firestone of Aureus Asset Management highlighted Abbott Laboratories’ strong pipeline and positive stock movement. Shannon Saccocia of NB Private Wealth recommended iShares U.S. Industrials ETF, while Joseph M. Terranova of Virtus Investment Partners selected Nu Holdings. The segment also analyzed the recent financial performances of these companies, showcasing their growth and key financial metrics.
